[1] |
Carey EJ, Ali AH, Lindor KD. Primary biliary cirrhosis[J]. Lancet, 2015, 386(10003):1565-1575.
|
[2] |
Webb GJ, Siminovitch KA, Hirschfield GM. The immunogenetics of primary biliary cirrhosis: a comprehensive review[J]. J Autoimmun, 2015, 64:42-52.
|
[3] |
Singal AK, Fang X, Kaif M, et al. Primary biliary cirrhosis has high wait-list mortality among patients listed for liver transplantation[J]. Transpl Int, 2017, 30(5):454-462.
|
[4] |
Weinmann A, Sattler T, Unold HP, et al. Predictive scores in primary biliary cirrhosis: a retrospective single center analysis of 204 patients[J]. J Clin Gastroenterol, 2015, 49(5):438-447.
|
[5] |
Parés A. Old and novel therapies for primary biliary cirrhosis[J]. Semin Liver Dis, 2014, 34(3):341-351.
|
[6] |
Floreani A, Tanaka A, Bowlus C, et al. Geoepidemiology and changing mortality in primary biliary cholangitis[J]. J Gastroenterol, 2017, 52(6):655-662.
|
[7] |
Chascsa D, Carey EJ, Lindor KD. Old and new treatments for primary biliary cholangitis[J]. Liver Int, 2017, 37(4):490-499.
|
[8] |
Hirschfield GM, Mason A, Luketic V, et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid[J]. Gastroenterology, 2015, 148(4): 751-761, e8.
|
[9] |
Trivedi PJ, Hirschfield GM, Gershwin ME. Obeticholic acid for the treatment of primary biliary cirrhosis[J]. Expert Rev Clin Pharmacol, 2016, 9(1):13-26.
|
[10] |
Tanaka A, Ma X, Yokosuka O, et al. Autoimmune liver diseases in the Asia-Pacific region: proceedings of APASL symposium on AIH and PBC 2016[J]. Hepatol Int, 2016, 10(6):909-915.
|
[11] |
Corpechot C. Primary biliary cirrhosis beyond ursodeoxycholic acid[J]. Semin Liver Dis, 2016, 36(1):15-26.
|
[12] |
Czul F, Levy C. Novel therapies on primary biliary cirrhosis[J]. Clin Liver Dis, 2016, 20(1):113-130.
|
[13] |
Yang H, Duan Z. Bile acids and the potential role in primary biliary cirrhosis[J]. Digestion, 2016, 94(3):145-153.
|
[14] |
Zhu GQ, Shi KQ, Huang S, et al. Network meta-analysis of randomized controlled trials: efficacy and safety of UDCA-based therapies in primary biliary cirrhosis[J]. Medicine, 2015, 94(11): e609.
|
[15] |
Dyson JK, Wilkinson N, Jopson L, et al. The inter-relationship of symptom severity and quality of life in 2 055 patients with primary biliary cholangitis[J]. Aliment Pharmacol Ther, 2016, 44(10):1039-1050.
|
[16] |
Raczyńska J, Habior A, Pączek L, et al. Primary biliary cirrhosis in the era of liver transplantation[J]. Ann Transplant, 2014, 19:488-493.
|
[17] |
Hosonuma K, Sato K, Yamazaki Y, et al. A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia[J]. Am J Gastroenterol, 2015, 110(3): 423-431.
|
[18] |
Gilroy RK, Lynch SV, Strong RW, et al. Confirmation of the role of the Mayo Risk Score as a predictor of resource utilization after orthotopic liver transplantation for primary biliary cirrhosis[J]. Liver Transpl, 2000, 6(6):749-752.
|
[19] |
Žampachová V, Honsová E. Recurrence of primary diseases after liver transplantation[J]. Cesk Patol, 2015, 51(4):170-174.
|
[20] |
Egawa H, Nakanuma Y, Maehara Y, et al. Disease recurrence plays a minor role as a cause for retransplantation after living-donor liver transplantation for primary biliary cirrhosis: a multicenter study in Japan[J]. Hepatol Res, 2013, 43(5):502-507.
|
[21] |
Shiba H, Wakiyama S, Futagawa Y, et al. Switching from tacrolimus to cyclosporine A to prevent primary biliary cirrhosis recurrence after living-donor liver transplantation[J]. Int Surg, 2013, 98(2):156-159.
|
[22] |
Bosch A, Dumortier J, Maucort-Boulch D, et al. Preventive administration of UDCA after liver transplantation for primary biliary cirrhosis is associated with a lower risk of disease recurrence[J]. J Hepatol, 2015, 63(6):1449-1458.
|